June 18, 2025

To,
Dy. General Manager
Department of Corporate Services,
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street, Fort, Mumbai – 400 001

Ref: Scrip Code: 532296

To,
The Manager – Listing,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Ref: Scrip Name: GLENMARK

Re: *Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015*

Dear Sir,

Sub.: U.S. FDA inspection at the Company's Facility at Monroe, North Carolina, USA

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the United States Food & Drug Administration (USFDA) conducted a GMP inspection at the Company's manufacturing facility situated in Monroe, North Carolina, USA from 09 June 2025 to 17 June 2025.

At the end of the inspection, the Company was issued a Form 483 with five (5) observations. All the observations are procedural in nature. There was no observation related to data integrity reported.

The Company will work in close collaboration with the agency to address the observations and will respond to the USFDA within the stipulated timeline. Please take the above information on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

HARISH VINAYAK KUBER
Digitally signed by HARISH VINAYAK KUBER
Date: 2025.06.18 08:51:43 +05'30'

Harish Kuber
Company Secretary & Compliance Officer